Lysogene S.A. (0RNL.L)
| Previous close | 0.5600 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8070 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Lysogene Announces the Extension of Deadline for the Submission of Offers
PARIS, March 24, 2023--Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that, upon decision of the judicial administrator, the deadline for submitting offers has been extended from March 15, 2023 to April 12, 2023 at 12:00 (noon).
- Business Wire
Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer
PARIS, February 03, 2023--Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced the appointment of Côme de La Tour du Pin, currently VP Finance/Chief Financial Officer ad interim, as Chief Financial Officer. He will replace Stéphane Durant des Aulnois who has decided to leave the Company to pursue other opportunities.
- Business Wire
Lysogene: Conversion of the Safeguard Proceedings Into Reorganization Proceedings
PARIS, January 25, 2023--Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces the conversion of the safeguard proceedings which has been in place since December 13, 2022 into reorganization proceedings.
